Jacqueline Birks

Summary

Affiliation: University of Oxford
Country: UK

Publications

  1. doi request reprint Galantamine for vascular cognitive impairment
    Jacqueline Birks
    Centre for Statistics inMedicine, University of Oxford, Oxford, UK
    Cochrane Database Syst Rev 4:CD004746. 2013
  2. doi request reprint Rivastigmine for vascular cognitive impairment
    Jacqueline Birks
    Centre for Statistics in Medicine, University of Oxford, Oxford, UK
    Cochrane Database Syst Rev 5:CD004744. 2013
  3. ncbi request reprint Evidence-based pharmacotherapy of Alzheimer's disease
    John Grimley Evans
    Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK
    Int J Neuropsychopharmacol 7:351-69. 2004
  4. ncbi request reprint Investigational treatment for vascular cognitive impairment
    Jacqueline Birks
    University of Oxford, Cochrane Dementia and Cognitive Improvement Group, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Expert Opin Investig Drugs 16:647-58. 2007
  5. doi request reprint Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis
    Celeste A de Jager
    Department of Physiology, Anatomy and Genetics, University of Oxford, UK
    Int J Geriatr Psychiatry 25:988-97. 2010
  6. ncbi request reprint Low vitamin B-12 status and risk of cognitive decline in older adults
    Robert Clarke
    Clinical Trial Service Unit, University of Oxford, University of Oxford, Oxford, United Kingdom
    Am J Clin Nutr 86:1384-91. 2007

Detail Information

Publications6

  1. doi request reprint Galantamine for vascular cognitive impairment
    Jacqueline Birks
    Centre for Statistics inMedicine, University of Oxford, Oxford, UK
    Cochrane Database Syst Rev 4:CD004746. 2013
    ....
  2. doi request reprint Rivastigmine for vascular cognitive impairment
    Jacqueline Birks
    Centre for Statistics in Medicine, University of Oxford, Oxford, UK
    Cochrane Database Syst Rev 5:CD004744. 2013
    ....
  3. ncbi request reprint Evidence-based pharmacotherapy of Alzheimer's disease
    John Grimley Evans
    Cochrane Dementia and Cognitive Improvement Group, University of Oxford, UK
    Int J Neuropsychopharmacol 7:351-69. 2004
    ..Memantine has been licensed in Europe for treatment of patients with moderately severe to severe Alzheimer's disease...
  4. ncbi request reprint Investigational treatment for vascular cognitive impairment
    Jacqueline Birks
    University of Oxford, Cochrane Dementia and Cognitive Improvement Group, Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK
    Expert Opin Investig Drugs 16:647-58. 2007
    ..For the purposes of this review, the authors focus on interventions that have been evaluated by randomised controlled trials...
  5. doi request reprint Retrospective evaluation of revised criteria for the diagnosis of Alzheimer's disease using a cohort with post-mortem diagnosis
    Celeste A de Jager
    Department of Physiology, Anatomy and Genetics, University of Oxford, UK
    Int J Geriatr Psychiatry 25:988-97. 2010
    ..We aimed to evaluate the new predementia-AD criteria through their retrospective application to the OPTIMA cohort with post-mortem (PM) confirmed diagnoses...
  6. ncbi request reprint Low vitamin B-12 status and risk of cognitive decline in older adults
    Robert Clarke
    Clinical Trial Service Unit, University of Oxford, University of Oxford, Oxford, United Kingdom
    Am J Clin Nutr 86:1384-91. 2007
    ..Elevated total homocysteine (tHcy) concentrations have been associated with cognitive impairment, but it is unclear whether low vitamin B-12 or folate status is responsible for cognitive decline...